N/A N=35 Evaluation of Vision After Vivity IOL Implantation With a Target of Slight Myopia in the Non-dominant Eye
Cataract
Primary: Binocular Near Visual Acuity — 0.14 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
Colitis, Ulcerative · Inflammatory Bowel Disease · IBD
Primary: Number of Participants to be Colectomy Free at 3 Months — 6 Participants
N/A N=28 Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Feasibility to Enroll and Retain Participants — 122 Participants
Phase 2 N=68 Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
Marginal Zone Lymphoma · MZL
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment — 68.2 Percentage of participants — p=<0.0001
N/A N=1,685 MOMENTUM 3 Continued Access Protocol
Advanced Refractory Left Ventricular Heart Failure
Primary: Event-Free Survival — 1320 Participants
N/A N=40 EM/PROTECT: Improving Depression in Elder Mistreatment Victims
Depression
Primary: Clinically Significant Depressive Symptoms (MADRS). — 24.21; 22.94; 12.59; 17.54 score on a scale — p=0.16
Phase 2 N=156 Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
COVID-19
Primary: Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7 — -2.04; -1.51; -1.24…
Phase 4 N=68 Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
Polycystic Kidney, Autosomal Dominant
Primary: Percent Change in Brachial Artery Flow-mediated Dilation (FMD-BA) — 1.14; 0.3 percent change
Phase 3 N=219 Mylan Insulin Glargine Study
Diabetes Mellitus, Type 1
Primary: Change in HbA1c — 0.18; 0.15 percentage of change
N/A N=63 Comparing Biofinity Toric Multifocal to Ultra Multifocal for Astigmatism
Astigmatism · Presbyopia
Primary: Ease of Lens Handling at Insertion — 8.6; 8.8 score on a scale
Phase 2 N=19 Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Major Depression
Primary: Model Adjusted Means for Hamilton Depression Rating Score — 20.22; 20.56 score on a scale — p=0.68
Phase 2 N=63 Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
COVID-19 Pulmonary Complications · COVID-19
Primary: Number of Participants With Respiratory Failure-free Survival — 27; 28 Participants — p=0.4099
Phase 4 N=191 Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
HIV Infections
Primary: Change in Normalized Composite Neurocognitive Test Score at Week 48 From Baseline — 0.20; 0.26; 0.31 total neurocognitive z-score — p=0.60
N/A N=144 Mindfulness During COVID-19
Migraine Disorders · Stress · Anxiety
Primary: Helpfulness of the Session — 89 percentage of participants
Phase 3 N=801 Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
Insomnia Disorder
Primary: Total no. of Subjects With at Least One TEAE — 53; 103; 55; 45 Participants